First‐in‐Man Study of Dedicated Bifurcation Sirolimus‐eluting Stent: 12‐month Results of BiOSS LIM® Registry

Publisher： John Wiley & Sons Inc

E-ISSN： 1540-8183|28|1|51-60

ISSN： 0896-4327

Source： JOURNAL OF INTERVENTIONAL CARDIOLOGY, Vol.28, Iss.1, 2015-02, pp. : 51-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First‐in‐man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus‐eluting stent in the treatment of patients with de novo coronary lesions: Clinical, Angiographic, and OCT outcomes of CREDIT‐1

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. S1, 2015-03 ,pp. : 744-751

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Supralimus ® sirolimus-eluting stent

By Lemos Pedro A   Bienert Igor  

Expert Review of Medical Devices, Vol. 10, Iss. 3, 2013-05 ,pp. : 295-300

Informa Healthcare

Access to resources Recommend Favorite

Bioabsorbable polymer‐coated sirolimus‐eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub‐study

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 7, 2015-12 ,pp. : 1141-1150

John Wiley & Sons Inc

Access to resources Recommend Favorite

First‐in‐Man Study of the Low‐Dose Paclitaxel Using the COBRA‐P Drug‐Eluting Coronary Stent System With a Novel Biodegradable Coating in De Novo Coronary Lesions

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 84, Iss. 7, 2014-12 ,pp. : 1101-1109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Moderate-Severe Renal Insufficiency Is a Risk Factor for Sirolimus-Eluting Stent Thrombosis

By  

Cardiology, Vol. 112, Iss. 3, 2008-08 ,pp. : 191-199

Karger

Access to resources Recommend Favorite